Petros Pharmaceuticals, Inc.
Datakwaliteit: 100%
PTPI
OTC
Manufacturing
Chemicals
€ 0,01
€ 0,00
(0,00%)
Marktkapitalisatie: 254.233,0
Prijs
€ 0,01
Marktkapitalisatie
254.233,0
Dagbereik
€ 0,01 — € 0,01
52-Weeksbereik
€ 0,00 — € 2,63
Volume
10.001
Openen € 0,01
50D / 200D Gem.
€ 0,01
17,81% below
50D / 200D Gem.
€ 0,02
67,03% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -4,86 M
Capital efficient — spends only 3,39% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)-12,20%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-179,74%
Onder sectorgemiddelde (-53,41%)
ROIC-270,52%
Net Margin-968,20%
Op. Margin-1844,57%
Veiligheid
Debt / Equity
N/A
Current Ratio2,22
Interest Coverage-32,05
Waardering
PE (TTM)
-0,04
Boven sectorgemiddelde (-1,48)
P/B Ratio0,08
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,0 | -1,5 |
| P/B | 0,1 | 1,6 |
| ROE % | -179,7 | -53,4 |
| Net Margin % | -968,2 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -12,20% | Revenue Growth (3Y) | -7,63% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 725.403,0 | Net Income (TTM) | -7,02 M |
| ROE | -179,74% | ROA | -103,82% |
| Gross Margin | 63,50% | Operating Margin | -1844,57% |
| Net Margin | -968,20% | Free Cash Flow (TTM) | -4,86 M |
| ROIC | -270,52% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2,22 |
| Interest Coverage | -32,05 | Asset Turnover | 0,11 |
| Working Capital | 3,37 M | Tangible Book Value | 3,37 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,04 | Forward P/E | N/A |
| P/B Ratio | 0,08 | P/S Ratio | 0,35 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -1911,77% | ||
| Market Cap | 254.233,0 | Enterprise Value | -5,82 M |
| Per Share | |||
| EPS (Diluted TTM) | -3,11 | Revenue / Share | 0,02 |
| FCF / Share | -0,11 | OCF / Share | -0,11 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 3,39% | FCF Conversion | 69,20% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | 5,11 M | 5,82 M | 5,99 M | 7,81 M |
| Net Income | -14,32 M | -8,16 M | -20,04 M | -8,99 M |
| EPS (Diluted) | -3,34 | -6,35 | -9,68 | -0,83 |
| Gross Profit | 3,90 M | 4,19 M | 3,70 M | 6,21 M |
| Operating Income | -17,68 M | -13,62 M | -19,92 M | -18,05 M |
| EBITDA | — | — | — | — |
| R&D Expenses | 2,62 M | 2,41 M | 1,74 M | 1,79 M |
| SG&A Expenses | 8,75 M | 9,26 M | 12,21 M | 15,59 M |
| D&A | 2,83 M | 3,28 M | 5,60 M | 6,88 M |
| Interest Expense | 560.909,0 | 515.311,0 | 596.018,0 | 368.660,0 |
| Income Tax | 0,0 | — | — | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Total Assets | 10,64 M | 33,80 M | 32,42 M | 67,39 M |
| Total Liabilities | 18,10 M | 21,32 M | 15,72 M | 31,85 M |
| Shareholders' Equity | -7,47 M | 12,07 M | 16,70 M | 35,54 M |
| Total Debt | — | — | — | — |
| Cash & Equivalents | 3,71 M | 13,30 M | 9,43 M | 23,85 M |
| Current Assets | 7,29 M | 20,39 M | 14,67 M | 30,54 M |
| Current Liabilities | 18,03 M | 10,77 M | 7,07 M | 30,98 M |
{"event":"ticker_viewed","properties":{"ticker":"PTPI","listing_kind":"stock","pathname":"/stocks/ptpi","exchange":"OTC","country":"US"}}